<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617820</url>
  </required_header>
  <id_info>
    <org_study_id>71836003</org_study_id>
    <nct_id>NCT05617820</nct_id>
  </id_info>
  <brief_title>Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY® (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site,&#xD;
      bioequivalence study with clinical endpoints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2022</start_date>
  <completion_date type="Anticipated">November 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder</measure>
    <time_frame>15 days</time_frame>
    <description>% Responders where a &quot;Responder&quot; is defined as a patient with: At least a 25% reduction from baseline in the sum of % basal/parabasal + % intermediate cells on vaginal cytology; and Vaginal pH &lt; 5.0 with a change from baseline vaginal pH of at least 0.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Most Bothersome Symptom</measure>
    <time_frame>15 days</time_frame>
    <description>Mean change from baseline to Day 15 in dyspareunia score (the self-identified most bothersome symptom in women with VVA). On a scale of 0 to 3, where 0 = none, 1=mild, 2=moderate and 3 = severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Success in Most bothersome symptom</measure>
    <time_frame>15 days</time_frame>
    <description>proportion of patients in each treatment group that are considered a Treatment Success at the end of the treatment period evaluated on Day 15. A &quot;Treatment Success&quot; is defined as a score of 0 or 1 on Day 15 for dyspareunia (the self-identified most bothersome symptom at baseline).On a scale of 0 to 3 where 0 = none, 1=mild, 2=moderate and 3 = severe</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1026</enrollment>
  <condition>Dyspareunia</condition>
  <arm_group>
    <arm_group_label>Estradiol vaginal inserts, 4 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estradiol vaginal inserts, 4 mcg. Insert vaginally once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMVEXXY® (estradiol vaginal inserts) 4 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMVEXXY® (estradiol vaginal inserts) 4 mcg. Insert vaginally once for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vaginal inserts</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo vaginal inserts. Insert vaginally once for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>Vaginal Insert, 4 mcg tablet</description>
    <arm_group_label>Estradiol vaginal inserts, 4 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imvexxy</intervention_name>
    <description>Estradiol 4 mcg Vaginal Insert</description>
    <arm_group_label>IMVEXXY® (estradiol vaginal inserts) 4 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle Vaginal Insert</description>
    <arm_group_label>Placebo vaginal inserts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed, IRB approved informed consent that meets all criteria of current FDA and local&#xD;
             regulations.&#xD;
&#xD;
          2. Females aged 40-75 years inclusive who are postmenopausal, with at least:&#xD;
&#xD;
               1. 12 months of spontaneous amenorrhea (women &lt;55 year of age with history of&#xD;
                  hysterectomy without bilateral oophorectomy prior to natural menopause must have&#xD;
                  Serum follicle-stimulating hormone (FSH) level &gt; 40 mIU/mL); or&#xD;
&#xD;
               2. 6 months of spontaneous amenorrhea with FSH levels &gt;40mIU/mL; or&#xD;
&#xD;
               3. At least 6 weeks postsurgical bilateral oophorectomy&#xD;
&#xD;
          3. Have less than or equal to 5% superficial cells on vaginal cytological smear.&#xD;
&#xD;
          4. Vaginal pH &gt; 5.0.&#xD;
&#xD;
          5. Moderate to severe symptom of vaginal pain associated with sexual activity considered&#xD;
             the most bothersome vaginal symptom (dyspareunia) of VVA by the patient at screening&#xD;
             visit. (i.e., a VVA Symptom Self-Assessment Questionnaire score of 2 or 3) (Appendix&#xD;
             B).&#xD;
&#xD;
          6. Women should be sexually active (for example, have sexual activity with vaginal&#xD;
             penetration within approximately one month of screening visit).&#xD;
&#xD;
          7. Women should anticipate having sexual activity (with vaginal penetration) during the&#xD;
             conduct of the study, and agree to at least one episode of sexual intercourse within&#xD;
             study days 10-13.&#xD;
&#xD;
          8. Baseline systolic blood pressure should be no greater than 150 mm Hg and diastolic&#xD;
             blood pressure no greater than 90 mm Hg.&#xD;
&#xD;
          9. Normal mammogram completed within 9 months before randomization and a normal clinical&#xD;
             breast examination prior to randomization in the study.&#xD;
&#xD;
         10. Patients who have underwent complete Hysterectomy, or in the case of patients with an&#xD;
             intact uterus (including patients who underwent a partial hysterectomy) the later must&#xD;
             have:&#xD;
&#xD;
               1. A documented papanicolaou (PAP) smear conducted within 12 months before&#xD;
                  randomization with no findings that the Investigator believes would&#xD;
                  contraindicate the use of topical vaginal estradiol.&#xD;
&#xD;
               2. Documented vaginal ultrasonography results within 3 months before randomization&#xD;
                  to confirm an inactive endometrial lining, defined as endometrial thickness &lt;4mm.&#xD;
&#xD;
         11. In the opinion of the Investigator, the patient will comply with the protocol and has&#xD;
             a high probability of completing the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Premenopasual, perimenopausal, pregnant or lactating patient or planning a pregnancy.&#xD;
&#xD;
          2. Significant history or current evidence of chronic infectious disease, system&#xD;
             disorder, organ disorder or other medical condition that in the Investigator's opinion&#xD;
             would place the study patient at undue risk by participation or could jeopardize the&#xD;
             integrity of the study evaluations.&#xD;
&#xD;
          3. Any clinically significant laboratory finding that, in the Investigator's opinion&#xD;
             would contraindicate the use of estradiol or compromise patients' safety.&#xD;
&#xD;
          4. Significant history of cholestatic jaundice, hypertension, coronary heart disease or&#xD;
             other serious heart problems, uncontrolled diabetes, hypercholesterolemia,&#xD;
             hypercalcemia, hypoparathyroidism, hypertriglyceridemia, systemic lupus erythematosus,&#xD;
             renal impairment, residual endometriosis posthysterectomy, asthma, epilepsy, migraine,&#xD;
             porphyria, hepatic hemangiomas that in the Investigator's opinion would place the&#xD;
             study patient at undue risk by participation or could jeopardize the integrity of the&#xD;
             study evaluations.&#xD;
&#xD;
          5. History of Protein C, Protein S, or antithrombin deficiency, or other thrombophilic&#xD;
             disorder.&#xD;
&#xD;
          6. Patients with known concurrent vaginal infections including but not limited to:&#xD;
             Candida albicans, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhea or&#xD;
             Gardnerella vaginalis.&#xD;
&#xD;
          7. Patients with active vaginal herpes simplex infection or have had an outbreak within&#xD;
             40 days before Screening&#xD;
&#xD;
          8. History of sexual abuse that in the opinion of the investigator may interfere with the&#xD;
             patient's assessment of vaginal pain with sexual activity.&#xD;
&#xD;
          9. Past or current diagnosis of endometrial hyperplasia.&#xD;
&#xD;
         10. Patients with known, suspected or current history of carcinoma of the breast.&#xD;
&#xD;
         11. Any patients with past or current undiagnosed vaginal bleeding or significant risk&#xD;
             factors for endometrial cancer.&#xD;
&#xD;
         12. History of estrogen-dependent neoplasia (e.g., endometrial cancer).&#xD;
&#xD;
         13. Any patients with hypersensitivity to estrogens.&#xD;
&#xD;
         14. Liver impairment or disease or kidney dysfunction or disorder (e.g., chronic renal&#xD;
             failure or hepatitis C).&#xD;
&#xD;
         15. History of thrombophlebitis, thrombosis, or thromboembolic disorders.&#xD;
&#xD;
         16. History of cerebrovascular accident, stroke, or transient ischemic attack.&#xD;
&#xD;
         17. History of Myocardial infarction or ischemic heart disease.&#xD;
&#xD;
         18. History or active presence of endocrine disease (except for controlled hypo- or&#xD;
             hyper-thyroidism or controlled non-insulin dependent diabetes mellitus). Patients who&#xD;
             are on a stable thyroid medication prior to the study should have normal baseline&#xD;
             thyroid function test results and expect not to have to change thyroid hormone regimen&#xD;
             during the study.&#xD;
&#xD;
         19. Any clinically significant abnormalities on screening physical exam, assessments, ECG,&#xD;
             or laboratory tests such as:&#xD;
&#xD;
               1. Vulvar or vaginal inflammatory condition such as a contact or allergic&#xD;
                  dermatitis, lichen sclerosis, or other pathological findings.&#xD;
&#xD;
               2. Presence of suspicious vulvar or vaginal lesions for dysplasia, malignancy, or&#xD;
                  other pathology other than atrophy.&#xD;
&#xD;
               3. History of active or chronic pelvic pain.&#xD;
&#xD;
               4. Painful genital warts or localized areas of ulceration.&#xD;
&#xD;
               5. Interstitial cystitis.&#xD;
&#xD;
               6. Unresolved findings suspicious for malignancy on the breast exam; incomplete&#xD;
                  mammogram result or unresolved findings suggestive of malignant changes or&#xD;
                  findings requiring follow-up on the pre-study mammogram.&#xD;
&#xD;
               7. Patients with an intact uterus who have an endometrial thickness of 4mm or&#xD;
                  greater.&#xD;
&#xD;
         20. Any prescription treatment for vaginal dryness/irritation within 2 weeks before&#xD;
             screening or any over the counter or natural remedies, vaginal lubricants or&#xD;
             moisturizers within 1 week before screening.&#xD;
&#xD;
         21. Taking inducers of CYP3A4 such as St. John's wort, anticonvulsants, phenylbutazone,&#xD;
             rifampin, rifabutin, nevirapine and efavirenz.&#xD;
&#xD;
         22. Taking inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole,&#xD;
             itraconazole, ritonavir, nelfinavir and grapefruit juice.&#xD;
&#xD;
         23. Fasting triglyceride levels &gt; 350 mg/dL.&#xD;
&#xD;
         24. History of radiation therapy or recent (within previous 6 weeks) surgical therapy to&#xD;
             the vaginal or cervical areas.&#xD;
&#xD;
         25. Any known or suspected allergies that in the Investigator's opinion would compromise&#xD;
             the safety of the patient.&#xD;
&#xD;
         26. Patients who have used vaginal hormonal products (i.e. rings, creams, gels) within the&#xD;
             4 weeks before Screening.&#xD;
&#xD;
         27. Patients who have used transdermal estrogen and/or progestin therapy within the 4&#xD;
             weeks before Screening.&#xD;
&#xD;
         28. Patients who have used oral estrogen, progestin, androgen or selective estrogen&#xD;
             receptor modular (SERM) containing drug products within 8 weeks before Screening&#xD;
             visit.&#xD;
&#xD;
         29. Intrauterine progestin therapy within 8 weeks before Screening.&#xD;
&#xD;
         30. Use of an intrauterine device within 12 weeks before screening visit.&#xD;
&#xD;
         31. Patients who have used estrogen pellet therapy or progestin implants/ injectable drug&#xD;
             therapy within the 6 months before Screening.&#xD;
&#xD;
         32. Patients who have engaged in sexual intercourse or used vaginal douching within 24&#xD;
             hours of the screening visit.&#xD;
&#xD;
         33. Inability to understand the requirements of the study and the relative information or&#xD;
             are unable or not willing to comply with the study protocol.&#xD;
&#xD;
         34. Patients who are unable or unwilling to give informed consent.&#xD;
&#xD;
         35. Current history of heavy smoking (more than 15 cigarettes per day) or use of&#xD;
             e-cigarettes.&#xD;
&#xD;
         36. Current use of marijuana.&#xD;
&#xD;
         37. Recent history of known alcohol or drug abuse, within one year start of the study.&#xD;
&#xD;
         38. Employees of the Investigator or research center or their immediate family members.&#xD;
&#xD;
         39. Receipt of any drug as part of a research study within 60 days before Screening.&#xD;
&#xD;
         40. Previous participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C Dias</last_name>
    <role>Study Director</role>
    <affiliation>Teva Pharmaceuticals USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US MED Info Medical Info</last_name>
    <phone>1-888-483-8279</phone>
    <email>USMedInfo@tevapharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Study Director</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site 10112</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10131</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10132</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10103</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10124</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10135</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10125</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10136</name>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <zip>06460</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10130</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10123</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10139</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10115</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10138</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10107</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10101</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10106</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10129</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10116</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10117</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10121</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10140</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10119</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10114</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10113</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10104</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10128</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10109</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10122</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10105</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10111</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10126</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10137</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10127</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10134</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10102</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10110</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10118</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10120</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10141</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10133</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 10108</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>March 27, 2023</last_update_submitted>
  <last_update_submitted_qc>March 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspareunia</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

